메뉴 건너뛰기




Volumn 33, Issue 12, 2009, Pages

Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; NILOTINIB;

EID: 70249103449     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.010     Document Type: Letter
Times cited : (10)

References (11)
  • 1
    • 0038092769 scopus 로고    scopus 로고
    • Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
    • Bumm T., Müller C., Al-Ali H.K., Krohn K., Shepherd P., Schmidt E., et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101 (2003) 1941-1949
    • (2003) Blood , vol.101 , pp. 1941-1949
    • Bumm, T.1    Müller, C.2    Al-Ali, H.K.3    Krohn, K.4    Shepherd, P.5    Schmidt, E.6
  • 2
    • 34648833625 scopus 로고    scopus 로고
    • The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
    • Deininger M.W., Cortes J., Paquette R., Park B., Hocchaus A., Baccarani M., et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110 7 (2007) 1509-1519
    • (2007) Cancer , vol.110 , Issue.7 , pp. 1509-1519
    • Deininger, M.W.1    Cortes, J.2    Paquette, R.3    Park, B.4    Hocchaus, A.5    Baccarani, M.6
  • 3
    • 34347225153 scopus 로고    scopus 로고
    • Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
    • Fabarius A., Haferlach C., Müller M.C., Erben P., Lahaye T., Giehl M., et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 92 (2007) 834-837
    • (2007) Haematologica , vol.92 , pp. 834-837
    • Fabarius, A.1    Haferlach, C.2    Müller, M.C.3    Erben, P.4    Lahaye, T.5    Giehl, M.6
  • 4
    • 35548939931 scopus 로고    scopus 로고
    • Philadelphia negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
    • De Melo V.A., Milojkovic D., Khorashad J.S., Marin D., Goldman J.M., Apperley J.F., et al. Philadelphia negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 110 (2007) 3086-3087
    • (2007) Blood , vol.110 , pp. 3086-3087
    • De Melo, V.A.1    Milojkovic, D.2    Khorashad, J.S.3    Marin, D.4    Goldman, J.M.5    Apperley, J.F.6
  • 5
    • 34447576744 scopus 로고    scopus 로고
    • Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case
    • Zeidan A., Kakati S., Anderson B., Barcos M., and Wetzler M. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genetics and Cytogenetics 176 (2007) 169-171
    • (2007) Cancer Genetics and Cytogenetics , vol.176 , pp. 169-171
    • Zeidan, A.1    Kakati, S.2    Anderson, B.3    Barcos, M.4    Wetzler, M.5
  • 6
    • 33750615550 scopus 로고    scopus 로고
    • Myelodysplastic syndrome and acute leukemia after imatinib mesylate therapy for chronic myeloid leukemia
    • Kovitz C., Kantarjian H.M., Garcia-Manero G., Abruzzo L.V., and Cortes J. Myelodysplastic syndrome and acute leukemia after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108 (2006) 2811-2813
    • (2006) Blood , vol.108 , pp. 2811-2813
    • Kovitz, C.1    Kantarjian, H.M.2    Garcia-Manero, G.3    Abruzzo, L.V.4    Cortes, J.5
  • 7
    • 34547691666 scopus 로고    scopus 로고
    • Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia
    • Zaccaria A., Valenti A.M., Donti E., Gozzetti A., Ronconi S., and Spedicato F. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 92 (2007) 564-565
    • (2007) Haematologica , vol.92 , pp. 564-565
    • Zaccaria, A.1    Valenti, A.M.2    Donti, E.3    Gozzetti, A.4    Ronconi, S.5    Spedicato, F.6
  • 8
    • 34447136847 scopus 로고    scopus 로고
    • Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
    • Fabarius A., Giehl M., Frank O., Spiess B., Zheng C., Müller M.C., et al. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. British Journal of Haematology 138 (2007) 369-373
    • (2007) British Journal of Haematology , vol.138 , pp. 369-373
    • Fabarius, A.1    Giehl, M.2    Frank, O.3    Spiess, B.4    Zheng, C.5    Müller, M.C.6
  • 9
    • 0032443366 scopus 로고    scopus 로고
    • Determination of cell fate by C-Abl activation in response to DNA damage
    • Kharbanda S., Yuan Z.M., Weichselbaum R., and Kufe D. Determination of cell fate by C-Abl activation in response to DNA damage. Oncogene 17 (1998) 3309-3318
    • (1998) Oncogene , vol.17 , pp. 3309-3318
    • Kharbanda, S.1    Yuan, Z.M.2    Weichselbaum, R.3    Kufe, D.4
  • 11
    • 70249128370 scopus 로고    scopus 로고
    • Nilotinib 800 Mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: result of a phase 2 trial of the GIMEMA CML
    • Abstract [0404]
    • Rosti G., Castagnetti F., Palandri F., Breccia M., Levato L., Capucci A., et al. Nilotinib 800 Mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: result of a phase 2 trial of the GIMEMA CML. Working Party Haematologica 93 sp1 (2008) Abstract [0404]
    • (2008) Working Party Haematologica , vol.93 , Issue.sp1
    • Rosti, G.1    Castagnetti, F.2    Palandri, F.3    Breccia, M.4    Levato, L.5    Capucci, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.